AstraZeneca PLC (AZN.L)
AZN.L on London Stock Exchange
5,421.00GBp
9:13am BST
5,421.00GBp
9:13am BST
Change (% chg)
42.00 (+0.78%)
42.00 (+0.78%)
Prev Close
5,379.00
5,379.00
Open
5,435.00
5,435.00
Day's High
5,440.00
5,440.00
Day's Low
5,392.00
5,392.00
Volume
186,043
186,043
Avg. Vol
1,975,548
1,975,548
52-wk High
5,585.07
5,585.07
52-wk Low
4,260.00
4,260.00
Consensus Recommendations
| Consensus Recommendation | Next Earnings (approx.) | Company Fiscal Year End Month |
Last Updated |
|---|---|---|---|
| Outperform | 0.83 | December | 21 Jun 2018 |
Analyst Recommendations and Revisions
| 1-5 Linear Scale | Current | 1 Month Ago |
2 Month Ago |
3 Month Ago |
|---|---|---|---|---|
| (1) BUY | 9 | 10 | 10 | 10 |
| (2) OUTPERFORM | 12 | 12 | 12 | 12 |
| (3) HOLD | 6 | 5 | 5 | 6 |
| (4) UNDERPERFORM | 4 | 4 | 3 | 3 |
| (5) SELL | 0 | 0 | 0 | 0 |
| No Opinion | 0 | 0 | 0 | 0 |
| Mean Rating | 2.16 | 2.10 | 2.03 | 2.06 |
Consensus Estimates Analysis
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| # of Estimates | Mean | High | Low | 1 Year Ago |
|
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Jun-18 | 11 | 5,397.27 | 5,632.60 | 5,054.58 | 5,378.78 |
| Quarter Ending Sep-18 | 11 | 5,666.90 | 6,075.11 | 5,343.00 | 5,385.24 |
| Year Ending Dec-18 | 31 | 22,365.40 | 23,199.00 | 20,818.00 | 22,298.80 |
| Year Ending Dec-19 | 31 | 23,856.20 | 26,486.00 | 21,913.00 | 24,121.40 |
| Earnings (per share) | |||||
| Quarter Ending Jun-18 | 10 | 0.83 | 1.07 | 0.59 | 0.64 |
| Quarter Ending Sep-18 | 10 | 0.86 | 0.99 | 0.65 | 0.85 |
| Year Ending Dec-18 | 32 | 3.37 | 3.79 | 2.41 | 3.82 |
| Year Ending Dec-19 | 33 | 3.90 | 4.94 | 3.03 | 4.42 |
| LT Growth Rate (%) | 6 | 9.84 | 16.70 | 3.70 | 6.08 |
Historical Surprises
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| Estimates vs Actual | Estimate | Actual | Difference | Surprise % |
|---|---|---|---|---|
| SALES (in millions) | ||||
| Quarter Ending Mar-18 | 5,282.61 | 5,178.00 | 104.61 | 1.98 |
| Quarter Ending Dec-17 | 5,473.40 | 5,777.00 | 303.60 | 5.55 |
| Quarter Ending Sep-17 | 5,972.46 | 6,232.00 | 259.54 | 4.35 |
| Quarter Ending Jun-17 | 5,043.25 | 5,051.00 | 7.75 | 0.15 |
| Quarter Ending Mar-17 | 5,408.17 | 5,405.00 | 3.17 | 0.06 |
| Earnings (per share) | ||||
| Quarter Ending Mar-18 | 0.60 | 0.48 | 0.12 | 20.19 |
| Quarter Ending Dec-17 | 0.84 | 1.30 | 0.46 | 54.91 |
| Quarter Ending Sep-17 | 1.07 | 1.12 | 0.05 | 4.22 |
| Quarter Ending Jun-17 | 0.80 | 0.87 | 0.07 | 8.40 |
| Quarter Ending Mar-17 | 0.82 | 0.99 | 0.17 | 20.86 |
Consensus Estimates Trend
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| Current | 1 Week Ago |
1 Month Ago |
2 Month Ago |
1 Year Ago |
|
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Jun-18 | 5,397.27 | 5,397.27 | 5,431.31 | 5,503.01 | 5,378.78 |
| Quarter Ending Sep-18 | 5,666.90 | 5,666.90 | 5,653.21 | 5,628.15 | 5,385.24 |
| Year Ending Dec-18 | 22,365.40 | 22,365.40 | 22,490.70 | 22,574.90 | 22,298.80 |
| Year Ending Dec-19 | 23,856.20 | 23,856.20 | 23,978.60 | 23,921.80 | 24,121.40 |
| Earnings (per share) | |||||
| Quarter Ending Jun-18 | 0.83 | 0.83 | 0.84 | 0.87 | 0.64 |
| Quarter Ending Sep-18 | 0.86 | 0.86 | 0.86 | 0.83 | 0.85 |
| Year Ending Dec-18 | 3.37 | 3.37 | 3.38 | 3.39 | 3.82 |
| Year Ending Dec-19 | 3.90 | 3.90 | 3.93 | 3.97 | 4.42 |
Estimates Revisions Summary
| Last Week | Last 4 Weeks | |||
|---|---|---|---|---|
| Number Of Revisions: | Up | Down | Up | Down |
| Revenue | ||||
| Quarter Ending Jun-18 | 0 | 0 | 1 | 4 |
| Quarter Ending Sep-18 | 0 | 0 | 3 | 2 |
| Year Ending Dec-18 | 0 | 0 | 3 | 10 |
| Year Ending Dec-19 | 0 | 0 | 5 | 8 |
| Earnings | ||||
| Quarter Ending Jun-18 | 0 | 0 | 1 | 2 |
| Quarter Ending Sep-18 | 0 | 0 | 1 | 1 |
| Year Ending Dec-18 | 0 | 1 | 5 | 8 |
| Year Ending Dec-19 | 0 | 1 | 5 | 10 |
Earnings vs. 
Estimates- What does AstraZeneca plc's deal with Pfizer mean for shareholders?
- Is Hikma Pharmaceuticals plc the best FTSE 100 healthcare stock to own after today’s update?
- 3 stocks to help you retire early
- Is it time to take profits on GlaxoSmithKline plc and AstraZeneca plc?
- These FTSE 100 stars have exploded in Q3! And they're not finished yet
- Why now is the perfect time to buy these 3 super income stocks